Abbott Labs (ABT) Market Value Declined While Iguana Healthcare Management Has Raised Stake by $2.39 Million; Rio Tinto Plc (RIO) Holding Has Increased by Nepsis Capital Management Inc

January 22, 2018 - By Linda Rogers

Nepsis Capital Management Inc increased its stake in Rio Tinto Plc (RIO) by 108.9% based on its latest 2017Q3 regulatory filing with the SEC. Nepsis Capital Management Inc bought 57,425 shares as the company’s stock declined 9.05% while stock markets rallied. The institutional investor held 110,157 shares of the precious metals company at the end of 2017Q3, valued at $5.20 million, up from 52,732 at the end of the previous reported quarter. Nepsis Capital Management Inc who had been investing in Rio Tinto Plc for a number of months, seems to be bullish on the $91.98B market cap company. The stock increased 0.35% or $0.195 during the last trading session, reaching $56.245. About 1.90 million shares traded. Rio Tinto plc (NYSE:RIO) has risen 43.73% since January 22, 2017 and is uptrending. It has outperformed by 27.03% the S&P500.

Stuart Weisbrod increased its stake in Abbott Labs (ABT) by 112.5% based on its latest 2017Q3 regulatory filing with the SEC. Iguana Healthcare Management Llc bought 45,000 shares as the company’s stock declined 3.42% while stock markets rallied. The hedge fund run by Stuart Weisbrod held 85,000 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $4.54M, up from 40,000 at the end of the previous reported quarter. Iguana Healthcare Management Llc who had been investing in Abbott Labs for a number of months, seems to be bullish on the $103.43B market cap company. The stock increased 0.19% or $0.11 during the last trading session, reaching $59.42. About 4.08M shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since January 22, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Among 21 analysts covering Rio Tinto (NYSE:RIO), 11 have Buy rating, 3 Sell and 7 Hold. Therefore 52% are positive. Rio Tinto had 48 analyst reports since August 5, 2015 according to SRatingsIntel. Liberum Capital downgraded Rio Tinto plc (NYSE:RIO) on Thursday, October 29 to “Sell” rating. The rating was upgraded by Macquarie Research to “Outperform” on Friday, August 7. The company was downgraded on Thursday, April 14 by CLSA. The firm has “Neutral” rating by Axiom Capital given on Friday, August 21. The firm has “Outperform” rating by Credit Suisse given on Wednesday, December 7. The rating was downgraded by JP Morgan on Monday, November 13 to “Neutral”. The stock of Rio Tinto plc (NYSE:RIO) earned “Hold” rating by Citigroup on Tuesday, October 17. Jefferies maintained the stock with “Buy” rating in Tuesday, June 20 report. The firm earned “Buy” rating on Friday, October 2 by Societe Generale. On Thursday, October 29 the stock rating was maintained by Cowen & Co with “Market Perform”.

Nepsis Capital Management Inc, which manages about $214.00M and $193.71M US Long portfolio, decreased its stake in Mazor Robotics Ltd (NASDAQ:MZOR) by 23,756 shares to 146,079 shares, valued at $7.21M in 2017Q3, according to the filing. It also reduced its holding in American Intl Group Inc (NYSE:AIG) by 10,765 shares in the quarter, leaving it with 68,862 shares, and cut its stake in Arcelormittal Sa Luxembourg.

Since August 1, 2017, it had 0 insider buys, and 6 insider sales for $22.86 million activity. Fussell Stephen R sold $9.73M worth of stock or 196,550 shares. Contreras Jaime sold $2.74M worth of Abbott Laboratories (NYSE:ABT) on Friday, September 22. $98,323 worth of Abbott Laboratories (NYSE:ABT) shares were sold by Bracken Sharon J.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 92 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Thursday, October 19 by Stifel Nicolaus. The rating was maintained by Barclays Capital on Thursday, September 28 with “Overweight”. On Tuesday, January 2 the stock rating was upgraded by Morgan Stanley to “Overweight”. The stock has “Buy” rating by Jefferies on Wednesday, October 18. The firm has “Buy” rating given on Friday, June 16 by Jefferies. The rating was maintained by Argus Research on Friday, July 21 with “Buy”. Morgan Stanley downgraded the shares of ABT in report on Monday, January 4 to “Equal-Weight” rating. The stock has “Outperform” rating by RBC Capital Markets on Friday, October 9. The rating was upgraded by BMO Capital Markets on Tuesday, December 12 to “Outperform”. The stock of Abbott Laboratories (NYSE:ABT) has “Equal-Weight” rating given on Thursday, October 19 by Morgan Stanley.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>